Bisphosphonates in osteoporosis: NICE and easy?
作者信息
Harvey Nicholas C, McCloskey Eugene, Kanis John A, Compston Juliet, Cooper Cyrus
机构信息
Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK; National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service Foundation Trust, Southampton, UK.
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK; Centre for Integrated Research in Musculoskeletal Ageing, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK.
出版信息
Lancet. 2017 Nov 18;390(10109):2243-2244. doi: 10.1016/S0140-6736(17)32850-7.
Abstract
摘要
相似文献
1
Bisphosphonates in osteoporosis: NICE and easy?双膦酸盐治疗骨质疏松症：简单易行？
Lancet. 2017 Nov 18;390(10109):2243-2244. doi: 10.1016/S0140-6736(17)32850-7.
2
Is it time for treat to target strategy in osteoporosis?骨质疏松症的治疗是否该采用目标治疗策略了？
Joint Bone Spine. 2016 Jul;83(4):381-3. doi: 10.1016/j.jbspin.2015.12.002. Epub 2016 Feb 10.
3
Management after first-line antiresorptive treatment for postmenopausal osteoporosis.绝经后骨质疏松症一线抗吸收治疗后的管理。
Joint Bone Spine. 2016 Jul;83(4):373-5. doi: 10.1016/j.jbspin.2016.02.004. Epub 2016 Mar 15.
4
Highly different risk estimates for atypical femoral fracture with use of bisphosphonates - debate must be allowed!使用双膦酸盐类药物时非典型股骨骨折的风险估计差异极大——必须允许进行辩论！
Acta Orthop. 2012 Aug;83(4):319-20. doi: 10.3109/17453674.2012.718517. Epub 2012 Aug 20.
5
Can long-term bisphosphonate use causes low-energy fractures? A case report.长期使用双膦酸盐会导致低能量骨折吗？一例病例报告。
Osteoporos Int. 2014 Feb;25(2):773-6. doi: 10.1007/s00198-013-2428-0. Epub 2013 Jul 4.
6
Treatment holidays in patients with postmenopausal osteoporosis: whom and when?
Endocrinol Nutr. 2012 Dec;59(10):573-4. doi: 10.1016/j.endonu.2012.07.009. Epub 2012 Sep 30.
7
Teriparatide treatment in an adult patient with hypophosphatasia exposed to bisphosphonate and revealed by bilateral atypical fractures.特立帕肽治疗曾接受双膦酸盐治疗的低磷酸酶血症成年患者，并由双侧非典型骨折表现。
Joint Bone Spine. 2018 May;85(3):365-367. doi: 10.1016/j.jbspin.2017.12.001. Epub 2017 Dec 12.
8
The 5-year follow-up of a cortical stress fracture resulting in a spontaneous atypical subtrochanteric femoral fracture in a female patient with severe osteoporosis and bisphosphonate therapy over 15 years.一名患有严重骨质疏松症且接受了超过 15 年双膦酸盐治疗的女性患者，因皮质骨应力性骨折导致自发性非典型转子下股骨干骨折，5 年随访结果。
Wien Klin Wochenschr. 2011 Nov;123(21-22):684-7. doi: 10.1007/s00508-011-0034-8. Epub 2011 Aug 15.
9
[Post hip fracture care].[髋部骨折后护理]
Praxis (Bern 1994). 2011 Jul 27;100(15):917-21. doi: 10.1024/1661-8157/a000614.
10
Severe low turnover osteoporosis.严重低转换型骨质疏松症。
Aging Clin Exp Res. 2007 Aug;19(4 Suppl):26-9.
引用本文的文献
1
[Exosome derived from human adipose-derived mesenchymal stem cells prevented bone loss induced by estrogen deficiency].[源自人脂肪间充质干细胞的外泌体预防雌激素缺乏诱导的骨质流失]
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Apr 18;57(2):217-226. doi: 10.19723/j.issn.1671-167X.2025.02.001.
2
Novel association between chronic obstructive pulmonary disease and osteoporosis: A prospective cross-sectional study.慢性阻塞性肺疾病与骨质疏松症之间的新型关联：一项前瞻性横断面研究。
World J Orthop. 2025 Feb 18;16(2):102101. doi: 10.5312/wjo.v16.i2.102101.
3
Ferrostatin-1 inhibits osteoclast differentiation and prevents osteoporosis by suppressing lipid peroxidation.铁死亡抑制因子1通过抑制脂质过氧化来抑制破骨细胞分化并预防骨质疏松症。
J Orthop Surg Res. 2025 Jan 30;20(1):117. doi: 10.1186/s13018-025-05544-2.
4
Recent advances in prophylactics and treatment of osteoporosis.骨质疏松症预防与治疗的最新进展
Prz Menopauzalny. 2022 Jun;21(2):133-137. doi: 10.5114/pm.2022.116646. Epub 2022 Jun 20.
5
Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group.是否到了考虑对绝经后妇女进行骨折风险人群筛查的时候了？国际骨质疏松基金会流行病学/生活质量工作组的立场文件。
Arch Osteoporos. 2022 Jun 28;17(1):87. doi: 10.1007/s11657-022-01117-6.
6
Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis through a Grade Analysis of Evidence.罗莫佐单抗与特立帕肽治疗绝经后骨质疏松症：通过证据分级分析的系统评价和荟萃分析。
Orthop Surg. 2021 Oct;13(7):1941-1950. doi: 10.1111/os.13136. Epub 2021 Oct 12.
7
Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women.基于 FRAX®的干预阈值在新加坡女性骨质疏松症管理中的成本效益。
Osteoporos Int. 2021 Jan;32(1):133-144. doi: 10.1007/s00198-020-05536-4. Epub 2020 Aug 14.
8
Hedgehog Inhibitors Suppress Osteoclastogenesis in In Vitro Cultures, and Deletion of in Macrophage/Osteoclast Lineage Prevents Age-Related Bone Loss.刺猬抑制剂抑制体外培养物中的破骨细胞生成，而巨噬细胞/破骨细胞谱系中 缺失可预防与年龄相关的骨丢失。
Int J Mol Sci. 2020 Apr 15;21(8):2745. doi: 10.3390/ijms21082745.
9
General and Specific Considerations as to why Osteoporosis-Related Care Is Often Suboptimal.骨质疏松相关护理往往不尽如人意的一般考虑因素和特殊考虑因素。
Curr Osteoporos Rep. 2020 Feb;18(1):38-46. doi: 10.1007/s11914-020-00566-7.
10
State of the art in osteoporosis risk assessment and treatment.骨质疏松风险评估与治疗的最新进展。
J Endocrinol Invest. 2019 Oct;42(10):1149-1164. doi: 10.1007/s40618-019-01041-6. Epub 2019 Apr 12.
本文引用的文献
1
UK clinical guideline for the prevention and treatment of osteoporosis.英国临床指南：骨质疏松症的预防和治疗。
Arch Osteoporos. 2017 Dec;12(1):43. doi: 10.1007/s11657-017-0324-5. Epub 2017 Apr 19.
2
Clinical assessment and management of multimorbidity: summary of NICE guidance.多重疾病的临床评估与管理：英国国家卫生与临床优化研究所指南摘要
BMJ. 2016 Sep 21;354:i4843. doi: 10.1136/bmj.i4843.
3
A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.基于FRAX的干预阈值系统评价：为国家骨质疏松症指南小组和国际骨质疏松症基金会编写的报告
Arch Osteoporos. 2016 Dec;11(1):25. doi: 10.1007/s11657-016-0278-z. Epub 2016 Jul 27.
4
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.长期双膦酸盐治疗患者的骨质疏松管理：美国骨与矿物质研究学会特别工作组报告
J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708.
5
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.长期使用双膦酸盐治疗后的转子下骨折：欧洲临床和经济骨质疏松症和骨关节炎学会以及国际骨质疏松基金会工作组报告。
Osteoporos Int. 2011 Feb;22(2):373-90. doi: 10.1007/s00198-010-1453-5. Epub 2010 Nov 18.
6
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.采用FRAX工具进行骨质疏松症管理的病例发现——英国的评估与干预阈值
Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1. Epub 2008 Aug 28.
7
The cost-effectiveness of alendronate in the management of osteoporosis.阿仑膦酸盐治疗骨质疏松症的成本效益
Bone. 2008 Jan;42(1):4-15. doi: 10.1016/j.bone.2007.10.019. Epub 2007 Nov 12.
Zotero 插件